Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Skin Problems Due to Treatment with Technology Are Associated with Increased Disease Burden Among Adults with Type 1 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cost of Treating Skin Problems in Patients with Diabetes who Use Insulin Pumps and/or Glucose Sensors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucose Sensor Accuracy After Subcutaneous Glucagon Injections Near to Sensor Site

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Insulin pump settings during breastfeeding in women with type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Comparison of Continuous Glucose Monitoring Accuracy Between Abdominal and Upper Arm Insertion Sites

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: In a 4-month follow-up survey, we examined whether treatment with continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) in adults with type 1 diabetes was associated with sustained skin problems and whether skin problems were associated with diabetes-related emotional distress.

RESEARCH DESIGN AND METHODS: A total of 111 adult patients completed a follow-up questionnaire concerning skin problems as a result of CSII and/or CGM use. The questionnaire included a patient-reported outcome measure, the Problem Areas in Diabetes (PAID) scale.

RESULTS: Current visible skin problems caused by CSII or CGM use were reported by 51 (46.0%) participants, in 34 (66.7%) of whom skin problems had been reported more than 4 months earlier. Seventy-two (64.9%) participants reported skin problems as a result of CSII use, whereas 38 (74.5%) reported skin problems owing to CGM use at some time. Itching was the most prevalent complaint. CSII-related itching was associated with a mean PAID score >20 (P = 0.01), and patients with more than one skin problem had an increased PAID score compared with those with one or no skin problems (P = 0.006).

CONCLUSIONS: More than half patients treated with CSII, CGM, or both had experienced skin problems during 4 months of follow-up that were associated with increased diabetes burden. Skin problems represent a persistent health issue affecting diabetes-specific emotional distress.

OriginalsprogEngelsk
TidsskriftDiabetes Technology & Therapeutics
Vol/bind21
Udgave nummer4
Sider (fra-til)215-221
Antal sider7
ISSN1520-9156
DOI
StatusUdgivet - 1 apr. 2019

ID: 56947139